Because asthma affects so many people worldwide, the asthma products industry is driven. As asthma rates climb worldwide, more individuals prefer simple asthma treatments. This impacts market growth.
The asthma product industry is driven by rapid breathing device technology advancements. Innovative products like smart inhalers, nebulizers with improved delivery methods, and user-friendly designs are transforming the industry.
Programs that educate consumers and healthcare staff about asthma impact the market. People are learning how vital it is to use devices appropriately, follow treatment programs, and recognize symptoms early, which boosts asthma device sales.
Air pollution and allergens increase asthma prevalence. As pollution rises, more individuals use breathing devices to manage their symptoms and feel better.
Number of asthmatic kids is a market element. Kids' asthma problems fuel the demand for age-appropriate inhalers and nebulizers, changing the market.
Government lung health initiatives and legislation impact the asthma product industry. Supportive legislation, financing, and public health activities make breathing equipment more inexpensive and accessible, changing market patterns.
The market is impacted by patient demand for small, easy-to-use devices. Small, portable, and easy-to-use inhalers and nebulizers are preferred by asthmatics. This affects asthma gadget development and popularity.
Biologics and specialized therapy impact asthma products. Targeted medications and biologics for particular asthma types vary the devices required for therapy.
The market depends on the healthcare system and treatment facility accessibility. Different healthcare access levels affect asthma product market trends. This is because certain locations lack amenities.
Research & development and new breathing products modify the market. Businesses get a competitive advantage by investing in innovative, valuable goods, which grows the market.
People with COPD or allergic rhinitis impact the asthma product industry. various common respiratory illnesses may need various devices for treatment.
Patients' treatment compliance and behavior impact the market. Easier-to-use devices with clear instructions and features that promote treatment compliance improve asthma management and boost demand.
Report Attribute/Metric | Details |
---|---|
Growth Rate | Â Â 4.7% |
Asthma Devices Market Size was valued at USD 4.00 Billion in 2023. The Global Asthma Devices industry is projected to grow from USD 4.21 Billion in 2024 to USD 7.45 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032).Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease. Increasing prevalence of asthma is one of the major drivers for the market growth.
The UK-based medical device company Acurable disclosed this in October 2022, saying it was helped to raise $10.8 million by its lead investor for the round, Kibo Ventures. The firm will use the funding to speed up AcuPebble SA100, which is a home-based sleep diagnostic tool that helps identify and track obstructive sleep apnea cases around the world. Moreover, Acurable would develop new drugs for cardiovascular diseases, asthma and COPD.
Adherium Limited has partnered with Trudell Medical Limited in August 2022 to treat U.S. patients with COPD.
A US$350 million Series A funding round was won by Arteria Therapeutics, a biotechnology company committed to helping asthmatics live normal lives in July of 2022. This money was expected by the company to fund phase 3 trials for a new asthma candidate that is said to have biologic-like efficacy in treating asthma through oral delivery.
Alkem launched Innohaler, a DPI device in March 2022 with an aim of improving comfort living for Asthma and COPD (Chronic Obstructive Pulmonary Disease) patients and narrowing the existing gaps in Asthma care across India. The introduction of this device marks Alkem’s entry into core inhalation treatments where it expects better medication will reach the lungs with every inhalation due to increased patient awareness and adherence program.
Life Wellness Healthcare announced an update on their online store that allows individuals with chronic obstructive pulmonary disease (COPD) be able to reduce their symptoms at home as of January 2022. Payment plans are available when purchasing AirPhysio devices, which are now ready for shipment throughout the United States.
For example, in March 2022, the US Food and Drug Administration approved Symbicort Inhalation Aerosol’s first generic version for treating two common pulmonary conditions, including asthma, among six-year-old and older patients.
For example, a Phase III clinical trial evaluating budesonide/glycopyrronium/formoterol inhalers effectiveness and safety among adults and adolescents who suffer from severe asthma and are inadequately controlled with the standard of care was initiated in March 2021 by AstraZeneca PLC in Mexico and the United States. The trial is expected to be completed in September 2023.
The global asthma devices market is segmented on the basis of type, technology, and end users.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)